Livingston Group Asset Management CO operating as Southport Capital Management increased its stake in AbbVie Inc (NYSE:ABBV) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,852 shares of the company’s stock after acquiring an additional 395 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in AbbVie were worth $1,049,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Sawyer & Company Inc grew its holdings in shares of AbbVie by 0.5% during the fourth quarter. Sawyer & Company Inc now owns 21,075 shares of the company’s stock valued at $1,866,000 after buying an additional 115 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA lifted its position in shares of AbbVie by 1.2% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 10,650 shares of the company’s stock worth $943,000 after purchasing an additional 125 shares in the last quarter. D.B. Root & Company LLC boosted its holdings in shares of AbbVie by 1.1% during the fourth quarter. D.B. Root & Company LLC now owns 11,564 shares of the company’s stock worth $1,023,000 after purchasing an additional 126 shares during the period. Brighton Jones LLC boosted its holdings in shares of AbbVie by 1.3% during the third quarter. Brighton Jones LLC now owns 9,986 shares of the company’s stock worth $756,000 after purchasing an additional 131 shares during the period. Finally, Private Ocean LLC boosted its holdings in shares of AbbVie by 3.8% during the third quarter. Private Ocean LLC now owns 3,796 shares of the company’s stock worth $288,000 after purchasing an additional 139 shares during the period. Institutional investors and hedge funds own 70.42% of the company’s stock.
ABBV stock traded up $0.18 during trading hours on Thursday, hitting $89.45. The company’s stock had a trading volume of 2,472,811 shares, compared to its average volume of 6,291,160. The stock has a 50 day moving average price of $88.51 and a two-hundred day moving average price of $76.87. AbbVie Inc has a 12 month low of $62.66 and a 12 month high of $91.99. The company has a market capitalization of $130.43 billion, a PE ratio of 11.31, a price-to-earnings-growth ratio of 2.08 and a beta of 0.97.
The business also recently announced a — dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a dividend of $1.18 per share. This is a positive change from AbbVie’s previous — dividend of $1.07. This represents a yield of 5.93%. The ex-dividend date of this dividend is Tuesday, January 14th. AbbVie’s dividend payout ratio (DPR) is 59.67%.
Several research analysts have weighed in on ABBV shares. ValuEngine upgraded shares of AbbVie from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Piper Jaffray Companies lifted their target price on shares of AbbVie from $81.00 to $90.00 in a research note on Friday, November 1st. Bank of America cut shares of AbbVie from a “buy” rating to a “neutral” rating in a report on Friday, January 3rd. UBS Group boosted their price target on shares of AbbVie from $79.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Finally, Citigroup upped their price target on shares of AbbVie from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. AbbVie has an average rating of “Hold” and an average price target of $86.33.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: What is the Rule of 72?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.